719results about How to "Induce apoptosis" patented technology

The present invention relates to internalizing peptides which facilitate the uptake and transport of cargo into the cytoplasm and nuclei of cells as well as methods for the identification of the peptides, and methods of use for the peptides. The internalizing peptides of the present invention are selected for their ability to efficiently internalize cargo into a wide variety of cell types both in vivo and in vitro.

The present invention provides peptides and peptidomimetics corresponding to part or to the entirety of the region encompassed by residues 360-386 of human p53, said peptides and peptidomimetics characterized by the ability to activate DNA binding of wild-type p53 and to select tumor-derived p53 mutants. Pharmaceutical compositions of the compounds of the invention and methods of using these compositions therapeutically are also provided.

Modified antibodies containing 2 or more H chain V domains and or more L chain V domains of a monoclonal antibody which can transduce a signal into cells by crosslinking a cell surface molecule, thereby serving as an agonist. Because of being usable as agonists for signal transduction, these modified antibodies are useful as, for example, preventives and/or remedies for various diseases such as cancer, inflammation, hormone disorders and blood diseases.

The present invention relates to methods for treating inflammation in body tissues. More specifically, certain disclosed methods relate to selectively inducing apoptosis in inflammatory immune cells. The methods are particularly suitable for treating inflamed atherosclerotic plaques. The techniques generally involve heating the cells with a catheter that is equipped to produce infrared radiation. The cells are heated for a sufficient time and at a sufficient temperature to induce programmed cell death.

Disclosed herein are methods and uses for preventing melanoma, reducing progression of atypical nevi, and inducing cell cycle arrest and/or apoptosis in a melanoma cell through oral and enteral administration of sulforaphane to subjects indicated to be at risk due to factor(s) such as medical history of atypical nevi, melanoma, or UV exposure. Sulforaphane can be administered orally as a safe and well-tolerated natural agent as a chemopreventive strategy in individuals with atypical melanocytic nevi.

Small molecule inhibitors of Stat3 and their derivatives are disclosed. Also described are methods to inhibit cell growth by use of Stat3 inhibitors, and the use of Stat3 inhibitors for the prevention and/or treatment of cancer. Further, inhibitors of Stat3 that also do not inhibit Stat1 are described as well as their derivatives. Methods of screening additional compounds for Stat3 inhibition activity and/or non-inhibition of Stat1 activity are also described herein.

The invention discloses a PD-L1 affinity peptide P1 with anti-tumour activity, which is the polypeptide obtained by phage display peptide library screening, wherein the amino acid sequence thereof is FPNWSLRPMNQM, and the molecular weight thereof is1520.7. The affinity peptide P1 with anti-tumour activity and aiming at a PD-L1 target disclosed by the invention has the advantage of being screened with a high flux by utilizing a phage display peptide library screening technology for the first time; and via an in-vivo tumour-bearing experiment for Kunming mice, the affinity peptide P1 disclosed by the invention is proved to have a great anti-tumour activity, can induce the internal tumour cell apoptosis of mice, and have an extremely high killing capacity for tumour cells. Via the affinity peptide P1 disclosed by the invention, new thoughts and theoretical basis are provided for research and development on medicines based on PD-L1.

The invention discloses a total bufogenin extract with antitumor function and also discloses a preparation method of the extract and application thereof in the preparation of antitumor medicines. The total bufogenin extract of the invention is prepared by organic solvent extraction, column chromatography separation and purification of dried toadskin; the content of total bufogenin is over 80 percent, wherein the content of resibufogenin is over 12 percent, the content of cinobufagin is over 4 percent, and the content of bufotalin is over 10 percent. Compared with the prior art, the invention eliminates bufotenine alkaloid which has irritation, is easy to cause hypersensitivity but has no antitumor activity, efficiently collects the effective part of total bufogenin which has significant antitumor activity, therefore pharmacological action is stronger, the clinical curative effect is higher and the toxic and side effect is lower. The total bufogenin extract can be prepared into various pharmaceutical preparations for clinical application, therefore the invention has the functions of killing tumor cells, inducing differentiation and apoptosis of tumor cells, inhibiting the neovascularization of tumor cells and lowering the neoplasm metastasis rate, etc.

Administration of low molecular weight (10,000-20,000 Daltons, or lower) pectins, particularly modified citrus pectins (MCP), like PectaSol-C reduces galectins-3 levels in vivo. Reduction of galectin-3 levels by MCP inhibits inflammation, inhibits fibrosis formation in organs and tissues, and inhibits cancer formation, progression, transformation and metastases. The reduction in circulating, serum and cellular galectin-3, inherently resulting from the administration of MCP, provides benefit over a spectrum of biological conditions, as evidenced by in vivo trials.

The present invention describes compositions and methods for inhibiting cell proliferation comprising a prolactin receptor antagonist and an agent that inactivates the HER2/neu signaling pathway, and methods of use thereof.

The present invention provides compounds that are inducers or inhibitors of apoptosis or apoptosis preceded by cell-cycle arrest. In addition, the present invention provides pharmaceutical compositions and methods for treating mammals with leukemia or other forms of cancer or for treating disease conditions caused by apoptosis of cells.

The invention discloses an siRNA of a targeted long-chain noncoding RNA DDX11-AS1 and applications thereof in liver cancer treatment. Through designing and synthesizing the siRNA of the DDX11-AS1 andtransfecting a liver cancer cell line with the siRNA, it is proved that the siRNA can targetedly inhibit expression of the DDX11-AS1, can significantly suppress liver cancer cell proliferation, invasion and migration and can induce liver cancer cell apoptosis. A novel target point for research and development of a liver cancer treatment medicine is provided.

The present invention provides compounds of formula (I) or (Ia) which are ligands binding to the HDM2 protein, inducing apoptosis and inhibiting proliferation, and having therapeutic utility in cancer therapy and prevention.

Compounds of formula (I) or (Ia) can be used as therapeutics for treating stroke, myocardial infarction, ischemia, multi-organ failure, spinal cord injury, Alzheimer's Disease, injury from ischemic events and heart valvular degenerative disease.

Moreover, compounds of formula (I) or (Ia) can be used to decrease the side effects from cytotoxic cancer agents, radiation and to treat viral infections.

The invention provides compounds and compositions useful for the modulation of certain enzymes. The compounds and compositions can induce of cell death, particularly cancer cell death. The invention also provides methods for the synthesis and use of the compounds and compositions, including the use of compounds and compositions in therapy for the treatment of cancer and selective induction of apoptosis in cells.

The present invention discloses recombinant soluble human tumore necrosis factor related death inducing ligand and its preparation process and application in preparing antitumor medicine. The present invention adopts human tonsil tissue mRNA as template to amplify TRAIL coding sequence, constitute engineering colibacillus for expressing rhsTRAIL and engineering saccharomycete, establish the rhsTRAIL engineering colibacillus fermentation, occlusion body washing and destination protein purification process and the engineering saccharomycete and destination protein purification process separately, and obtain pure rhsTRAIL product, which has molecular weight of 19.6-24 KD and exists in both monomer and dimmer. The rhsTRAIL can induce death of several kinds of cancer cells outside body, inhibit amplification of liver cancer cell in tumor loading mouse obviously and kill tumor cell selectively, so that it may be used in preparing effective antitumor medicine.

According to the present invention, an apoptosis-inducing agent for prostate cancer comprising REIC/Dkk-3 DNA or an REIC/Dkk-3 protein, and a therapeutic agent for prostate cancer and an agent for inhibiting prostate cancer metastasis that comprise such apoptosis-inducing agent are provided.

An apoptosis-inducing agent for prostate cancer, comprising, as an active ingredient, an REIC/Dkk-3 protein (a) or (b) or REIC/Dkk-3 DNA (c) or (d):

• • (a) a protein consisting of the amino acid sequence represented by SEQ ID NO: 2;
  • (b) a protein consisting of an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO: 2 by substitution or deletion of 1 or more amino acids;
  • (c) DNA consisting of the nucleotide sequence represented by SEQ ID NO: 1; or
  • (d) DNA that hybridizes under stringent conditions to DNA consisting of a nucleotide sequence complementary to the nucleotide sequence represented by SEQ ID NO: 1 and encodes a protein having apoptosis activity; and
  • a therapeutic agent for prostate cancer comprising such apoptosis-inducing agent are provided

The invention relates to a medicament in combination of a disulfiram preparation and copper, having an anti-tumor function. The combination of disulfiram and copper in the invention plays a role in treating tumor cells, belonging to the technical field of medicaments. The anti-tumor combination medicament comprises disulfiram or derivatives thereof and copper and any one or more optional medicinal vectors, which are used simultaneously, respectively or sequentially; the dosage of the disulfiram in each single medicament ranges from 2 to 200 mg/kg or equals to the equivalent dosage of disulfiram derivatives; and the copper comprises micro copper ions contained in the human body and other absorbable forms of copper irons, wherein the dosage of the copper in each single medicament is 0.1-5 mg per day. The combination medicament disclosed by the invention has remarkable effect in treating tumors and reduced toxic and side effects.

Anti-TRAIL-R1 and R2 antibodies or functional fragments thereof, having at least one property selected from the following (a) to (c) of: (a) having activity to induce apoptosis in carcinoma cells expressing TRAIL-R1 and/or TRAIL-R2; (b) not having effect on normal human cells expressing TRAIL-R1 and/or TRAIL-R2; and (c) not inducing human hepatocyte toxicity, and an anti-TRAIL-R1 and R2 antibodies or functional fragments thereof, having the following properties: having activity to induce apoptosis in carcinoma cells independently of exogenous factors and as a monomer of an antibody.

The invention provides an acetone extract, chloroform extract or hexane extract of Angelicae sinensis and/or the active components purified therefrom, such as n-butylidenephthalide, which are effective in treating cancers.

The invention provides an ubiquitin ligase and the application thereof, the ubiquitin ligase is protein described as follows: protein composed of amino acid sequence shown as the SEQ ID NO:2; Or protein composed of amino acid sequence shown as the SEQ ID NO:2 with replacement, deletion and/or adding one or more amino acids and has a same ubiquitin ligase activity with the amino acid sequence shown as the SEQ ID NO:2. The invention also provides a method for preparing the ubiquitin ligase, And also provides polynucleotides of amino acid sequence for coding the ubiquitin ligase protein, gene engineering carrier comprising the polynucleotides, host cells, Also provides antibody specially combined with the ubiquitin ligase, And applications of the ubiquitin ligase, the polynucleotides, the carrier and the antibody are also provided.

The invention belongs to the technical field of anticancer drugs, and particularly discloses a manganese dioxide/glucose oxidase @ hyaluronic acid composite anticancer material. The composite anticancer material comprises a core and a shell covering the core, wherein the core comprises a manganese dioxide nanosheet and glucose oxidase modified on the surface of the manganese dioxide nanosheet; andthe shell is hyaluronic acid. The invention further provides preparation and an application of the anticancer material. Studies find that the composite material can effectively and synergistically improve selectivity of cancer cells and normal cells, efficiently and specifically kill the cancer cells, and induce apoptosis of many cancer cells at a low dose through synergy of innovative componentsand composite morphology of the components; and in addition, the material does not influence metabolism of the normal cells basically and has small toxic and side effects.